Abstract
This is a three arm Phase I study within the Pacific Pediatric Neuro-Oncology Consortium
(PNOC).
This study will look to determine the safety and recommended phase 2 dose of the modified
measles virus (MV-NIS) in children and young adults with recurrent medulloblastoma or
atypical teratoid rhabdoid tumor (ATRT).
